...to prevent it from reaching the market. In 2015, Sorrento Therapeutics Inc. (NASDAQ:SRNE) sold its Igdrasol Inc....

...inducer of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) expression. In May, NantWorks acquired Sorrento's IgdraSol Inc....

...NantWorks will acquire the Igdrasol Inc. subsidiary of Sorrento for $90 million up front and up to...

...Samyang granted Sorrento’s Igdrasol Inc. subsidiary exclusive rights to commercialize cancer drug Cynviloq in South America. Sorrento...

...Sorrento Therapeutics Inc. (NASDAQ:SRNE) gained $1.51 (13%) to $13.01 on news that its Igdrasol Inc. subsidiary will...

...to Cynviloq in the U.S., EU, Mexico, Canada and Australia through its September acquisition of Igdrasol Inc....

...Samyang granted EU rights to Sorrento and Igdrasol Inc. and U.S. rights to Igdrasol. Sorrento acquired Igdrasol...

...previously approved products. Sorrento gained exclusive, U.S. rights to Cynviloq through its September acquisition of Igdrasol Inc....

...previously approved products. Sorrento gained exclusive, U.S. rights to Cynviloq through its September acquisition of Igdrasol Inc....

...treat NSCLC and mBC. In September, Sorrento acquired exclusive, U.S. rights through the acquisition of Igdrasol Inc....